Metabolism Disorder TRIZ Cases

Covalent glycoside-surfactant peptide modification extends duration, improves bioavailability, and reduces aggregation in insulin resistance therapy.

Pre-enriched stem cells deliver healthy mitochondria to pancreatic tissue, improving energy production and extending therapeutic effect.

Sublingual insulin-related peptides reduce antigenic response and delay Type 1 diabetes onset while avoiding traumatic daily injections.

Optimized semaglutide dosing improves weight reduction while lowering nausea and other gastrointestinal adverse events in weight management.

Dual receptor agonists extend peptide half-life while limiting fibrillation and potency loss, enabling once-weekly treatment of diabetes and obesity.

Zwitterionic polymer particles improve mucosal interaction and intestinal uptake, helping proteins and peptides achieve better oral delivery.

A retro-Michael resistant albumin linker keeps a GLP-1/GIP/glucagon tri-agonist stable, long-acting, and effective at ultra-low doses.

CRISPR RNP disruption of Nrip1 in adipose progenitor cells creates thermogenic adipocytes that improve glucose tolerance and lower liver triglycerides.

Peptide modifications with albumin binding and stability features extend amylin agonist half-life and improve receptor selectivity for metabolic therapy.

An oral GLP-1 formulation uses oils, bile salts, and sodium bicarbonate to avoid injection side effects while treating diabetes.

Fragment-based solid phase synthesis shortens glucagon production while improving purity and yield through controlled coupling and RP-HPLC purification.

Monoclonal anti-GLP-1R antibodies replace short-lived peptide antagonists with long half-life receptor blocking and less frequent dosing.

Complex-type glycan rhGAA with bis-M6P and an enzyme stabilizer extends motor and pulmonary function gains in Pompe disease.

Immunoprevalent T1D epitopes are presented on tolerogenic cells to suppress CD8+ T cell attack and protect pancreatic β cells.

Sub-nanomolar anti-ZnT8 antibodies inhibit zinc transport and enable HTRF measurement of cellular ZnT8 levels for diabetes research.

A single-domain heavy-chain antibody improves GDF15 specificity and blocks GDF15-GFRAL binding for diagnosis and treatment.

Taking medium chain triglycerides about 30 minutes before a meal lowers postprandial glucose without raising insulin resistance or hypoglycemia risk.

GMD lowers blood glucose by boosting GLP-1, activating hepatic glycolysis, and inhibiting gluconeogenesis to improve insulin resistance.

PLK inhibitor treatment suppresses proliferative CHGA-negative cells, improving insulin-producing cell purity for safer diabetes transplantation.

Combined oral SGLT1 and SGLT2 inhibition limits intestinal absorption and kidney reabsorption of glucose to address hyperglycemia and liver lipid buildup.

A preformed solid statin inside an omega-3 liquid soft capsule prevents incompatibility and degradation while preserving bioavailability.

Locked nucleoside antisense conjugates with ASGPR-binding ligands improve liver targeting, suppress PCSK9, and lower toxicity risk.

Adding 0.5%-5% polyhalite to fish feed improves protein use, cuts feed cost, and reduces nitrogenous and phosphorous waste.

A stable C66 crystal form with defined XRD peaks improves solubility, flow, and scalability for diabetic nephropathy drug formulation.

Colon-targeted oxygen, redox, and pH modulation shifts gut bacteria to support weight management without invasive bariatric surgery.

A dual A2A agonist and A3 antagonist boosts lipolysis and thermogenesis in adipocytes to reduce fat without CNS stimulation.

Raising GDF11 levels helps limit weight gain, improve glucose tolerance, and reduce hepatosteatosis in obesity- and age-related metabolic disease.

IGF-2 dosing boosts beta cell function and insulin production to maintain normal glucose levels beyond daily insulin therapy.

Pancreatic protein-derived peptides bind MHC class II without antigen processing to suppress beta cell autoreactive T-cells in type 1 diabetes.

Insoluble manganese compounds adsorb uric acid in the digestive tract to lower blood and gut levels without added systemic side effects.

A capric-lauric mixed structural lipid replaces harmful caprylic-based fats to improve glucose homeostasis and regulate lipid metabolism.

Acidic buffered exendin (9-39) with tonicity control reduces peptide aggregation and improves pharmacokinetics for hyperinsulinemic hypoglycemia.

Crystalline PCSK9 inhibitor salts reduce instability and hygroscopicity while improving purity, handling, and oral dosage formulation.

A cleaved BRINP2-related peptide lowers food intake and body weight, offering a targeted obesity treatment with less peptide modification complexity.

Short QBP1-derived peptides block hIAPP oligomer and fibril formation, protecting pancreatic β-cells while improving solubility and manufacturability.

With-meal mulberry leaf extract dosing lowers postprandial glucose and insulin response while improving daily meal integration.

A crosslinked polymer with pKa-lowering acidic groups boosts GI potassium binding to lower serum potassium with fewer side effects.